This study reveals the critical role of DLL3 in neuroendocrine prostate cancer, providing clear molecular targets and experimental design foundations for patient screening and the construction of gene-edited animal models for prostate cancer patients.
Literature Overview
This article, "DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives," published in the journal Drugs, systematically explores DLL3-targeted therapeutic strategies for aggressive variant prostate cancer (AVPC) and neuroendocrine prostate cancer (NEPC) in advanced stages. The article reviews the entire process from biological mechanisms to clinical translation, analyzing early clinical data from multiple therapeutic platforms including antibody-drug conjugates (ADCs), bispecific/trispecific T-cell engagers (TCEs), and radiopharmaceuticals. It emphasizes the critical significance of biomarker-guided patient stratification for improving therapeutic efficacy.Background Knowledge
1. The pain point in prostate cancer addressed by this study is that, although androgen receptor (AR) signaling pathway inhibition is the standard therapy, some tumors undergo lineage plasticity to transform into AR-independent neuroendocrine phenotypes, leading to resistance against existing treatments and extremely poor prognosis. 2. The current bottleneck in DLL3 research lies in the lack of standardized detection thresholds, and the expression heterogeneity of DLL3 across different subtypes (e.g., dedifferentiated adenocarcinoma vs. pure neuroendocrine carcinoma) has not been fully elucidated, limiting precision medicine applications. 3. The entry point for this topic is DLL3, an inhibitory Notch ligand that is lowly expressed in normal adult tissues but abnormally highly expressed in neuroendocrine malignancies, possessing excellent theranostic (diagnostic and therapeutic integrated) potential. The article deeply analyzes the molecular association between TP53, RB1 loss, and DLL3 upregulation, pointing out that DLL3 is not only a biomarker for diagnosing neuroendocrine prostate cancer but also a highly promising therapeutic target.
Research Methods and Core Experiments
The authors systematically reviewed existing preclinical and clinical data, integrating multi-dimensional evidence from tissue immunohistochemistry (IHC), single-cell transcriptomics, and circulating tumor cell (CTC) analysis. The study focused on evaluating expression differences of DLL3 in benign prostate, localized prostate cancer, and metastatic castration-resistant prostate cancer (mCRPC). Patient-derived xenograft (PDX) models were utilized to validate the efficacy of DLL3-targeted agents (such as Rova-T, Tarlatamab, HPN328). Key evidence shows that high DLL3 expression is highly correlated with RB1 loss and neuroendocrine features. Furthermore, in DLL3-positive models, DLL3-targeted TCEs induced significant tumor regression, even killing neighboring DLL3-negative cells via the bystander effect.Key Conclusions and Perspectives
Research Significance and Prospects
From a research perspective, these findings offer guidance for drug development, suggesting a future focus on developing safer DLL3-targeted agents and establishing stratified clinical trial designs based on DLL3 expression levels. For clinical monitoring, combining liquid biopsy to detect dynamic changes in DLL3 may help identify lineage transformation early. In terms of disease modeling, constructing gene-edited mouse models carrying TP53/RB1 double knockouts with high DLL3 expression will accelerate the drug screening process.
Conclusion
This article comprehensively evaluates the potential of DLL3 as a therapeutic target for advanced prostate cancer, noting that while traditional chemotherapy has limited efficacy, novel immunotherapies targeting DLL3 offer new hope for patients with neuroendocrine prostate cancer. The study emphasizes that the key to success lies in precisely identifying populations with high DLL3 expression, which requires standardized detection methods and stricter enrollment criteria. In the translation from laboratory to clinic, utilizing gene-edited animal models to simulate the DLL3-driven tumor microenvironment, combined with immunohistochemistry and molecular imaging techniques, will be the cornerstone for optimizing treatment strategies. In the future, with the iteration of DLL3-targeted drugs and the exploration of combination therapy regimens, it is expected to significantly improve the survival prognosis of patients with this refractory related disease, reshaping the treatment landscape of prostate cancer.
